KAN-001 / Kanvas Biosci, UT MD Anderson Cancer Center - LARVOL DELTA

KAN-001, a Defined Live Biotherapeutic Product (LBP) for NSCLC, Enhances ICI Response in Preclinical Models and Demonstrates Manufacturing Consistency and Strain-Resolved Viability (SITC 2025) - "KAN-001 will be administered orally in an encapsulated frozen liquid formulation with induction and maintenance dosing. Microbiome profiling will be performed throughout the trial to characterize host-microbiome interactions and identify potential response biomarkers.Acknowledgements We thank Nadim Ajami and Jennifer Wargo of the MD Anderson Cancer Center for their continued support of the KAN-001 program.Ethics Approval The in vivo mouse study was approved by the Institutional Animal Care Committee (CIPA) and carried out in compliance with the Canadian Council at the CRCHUM."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

KAN-001, a defined live biotherapeutic product (LBP) for NSCLC, enhances ICI response in preclinical models and demonstrates manufacturing consistency and strain-resolved viability (SITC 2025) - "KAN-001 will be administered orally in an encapsulated frozen liquid formulation with induction and maintenance dosing. Microbiome profiling will be performed throughout the trial to characterize host-microbiome interactions and identify potential response biomarkers.Acknowledgements We thank Nadim Ajami and Jennifer Wargo of the MD Anderson Cancer Center for their continued support of the KAN-001 program.Ethics Approval The in vivo mouse study was approved by the Institutional Animal Care Committee (CIPA) and carried out in compliance with the Canadian Council at the CRCHUM."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Kanvas Biosciences Secures Additional $12.5M to Advance Its Novel, Microbiome-Based Immuno-oncology Drug Candidates to IND Filing (PRNewswire) - "Kanvas Biosciences...announced it has raised $12.5 million in additional funding...The fresh capital closely follows a June 2023 round and brings Kanvas's total funding to $29.5 million. The funding will be used to further develop the company's spatial biology platform and advance two novel therapeutics in its Immuno-oncology Program, KAN-001 and KAN-003 — KAN-001 to an Investigational New Drug (IND) filing in 2025....Kanvas is collaborating with The University of Texas MD Anderson Cancer Center and its Platform for Innovative Microbiome and Translational Research (PRIME-TR) to conduct additional preclinical studies for KAN-001 to optimize the drug's formulation and prepare it for an IND filing in 2025, preparatory to recruiting the first patients for a clinical trial the same year."

Financing • IND • Licensing / partnership • Oncology • Solid Tumor